Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kameswara Tatineni

Psychiatry Battle Creek, MI Medical Doctor

NPI 1700977154 CMS profile 31784

126 College St, Ste C, Battle Creek, MI 49037

Open in the dashboard

General payments

$99,252

1,152 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kameswara Tatineni of Battle Creek, MI is reported in the CMS Open Payments database as having received $99,252 across 1,152 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,887 188
2024 General $10,824 159
2023 General $11,615 152
2022 General $12,222 144
2021 General $16,932 192
2020 General $15,238 146
2019 General $28,535 171

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kameswara Tatineni
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Kameswara Tatineni were reported at $3,887. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Kameswara Tatineni Psychiatry median Middle half National median
2019 $28,535 $184 $59–$605 $163
2020 $15,238 $119 $36–$372 $114
2021 $16,932 $143 $43–$576 $132
2022 $12,222 $153 $50–$590 $149
2023 $11,615 $170 $56–$651 $160
2024 $10,824 $179 $57–$673 $164
2025 $3,887 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $31,234 218 payments
  2. ITI, Inc. $25,633 162 payments
  3. Teva Pharmaceuticals USA, Inc. $18,017 66 payments
  4. Sunovion Pharmaceuticals Inc. $6,068 53 payments
  5. Allergan Inc. $5,845 44 payments
  6. Alkermes, Inc. $3,048 143 payments
  7. AbbVie, Inc. $1,993 40 payments
  8. Vanda Pharmaceuticals Inc. $1,477 95 payments
  9. Janssen Pharmaceuticals, Inc $910 48 payments
  10. Lundbeck LLC $840 69 payments
  11. Other $4,186 214 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $75,878 52 payments
  2. Food and Beverage $18,697 1,082 payments
  3. Travel and Lodging $4,582 12 payments
  4. Education $96 6 payments
Products named General payments · program years 2019–2025
  1. ABILIFY MAINTENA $30,374 158 payments
  2. CAPLYTA $25,177 140 payments
  3. UZEDY $17,401 40 payments
  4. LATUDA $6,021 52 payments
  5. VRAYLAR $5,899 47 payments
  6. ARISTADA Cns $2,678 136 payments
  7. ARISTADA Cns $2,678 136 payments
  8. ARISTADA Cns $2,389 121 payments
  9. ARISTADA Cns $2,389 121 payments
  10. LYBALVI $2,320 94 payments
  11. Other $17,756 871 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

2,719

Median for Psychiatry: 574

Drug cost

$432,272

Median for Psychiatry: $27,624

Branded share of claims

22%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 13 $98,634
Vraylar Cariprazine Hcl Brand 43 $66,966
Caplyta Lumateperone Tosylate Brand 30 $47,819
Abilify Maintena Aripiprazole Brand 16 $43,870
Nuedexta Dextromethorphan Hbr/Quinidine Brand 23 $25,600
Rexulti Brexpiprazole Brand 11 $24,477
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 120 $19,191
Lybalvi Olanzapine/Samidorphan Malate Brand 12 $19,065
Latuda Lurasidone Hcl Brand 11 $15,036
Xanax Alprazolam Brand 17 $13,767

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$189,524

Medicare's payments for the services billed

Medicare patients

147

Average age 66

Services billed

2,315

92 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 67%
Arthritis 52%
Diabetes 37%
COPD 37%
Alzheimer's or dementia 29%
Chronic kidney disease 28%
Heart failure 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UZEDY
$8,315 — —
ARISTADA
$433 — —
CAPLYTA
$411 30 —
REXULTI
$338 11 —
Austedo XR
$229 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

1,152 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record